Cargando…

Survival Benefit of Perioperative Systemic Chemotherapy for Patients With N0 to N1 NSCLC Having Synchronous Brain Metastasis

INTRODUCTION: In stage IV NSCLC with solitary or oligometastatic brain metastasis, surgical resection of the primary and definitive management of the brain metastasis is an accepted standard. However, the effect of systemic chemotherapy after surgical resection on overall survival is not well-establ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vedire, Yeshwanth R., Shin, Sarah, Groman, Adrienne, Hennon, Mark, Dy, Grace K., Yendamuri, Sai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238748/ https://www.ncbi.nlm.nih.gov/pubmed/37275564 http://dx.doi.org/10.1016/j.jtocrr.2023.100522

Ejemplares similares

Geographical Disparities in Esophageal Cancer Incidence and Mortality in the United States
por: Vedire, Yeshwanth, et al.
Publicado: (2023)

Obesity and lung cancer—a narrative review
por: Vedire, Yeshwanth, et al.
Publicado: (2023)

Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer
por: Vedire, Yeshwanth Reddy, et al.
Publicado: (2023)

Visceral Obesity in Non-Small Cell Lung Cancer
por: Nitsche, Lindsay, et al.
Publicado: (2022)

Skeletal muscle index is associated with long term outcomes after lobectomy for non-small cell lung cancer
por: Vedire, Yeshwanth, et al.
Publicado: (2023)

Advances in lung cancer surgery
por: Hennon, Mark W., et al.
Publicado: (2012)

Immunoprofiling bronchoalveolar lavage cells reveals multifaceted smoking-associated immune dysfunction
por: Smith, Randall, et al.
Publicado: (2023)

Survival benefit of perioperative chemotherapy for T1–3N0M0 stage esophageal cancer: a SEER database analysis
por: Shao, Yue, et al.
Publicado: (2021)

肺癌外科手术进展
por: Hennon, Mark W., et al.
Publicado: (2013)

Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy
por: Bang, Hyun Jin, et al.
Publicado: (2023)

Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC
por: Komiya, Takefumi, et al.
Publicado: (2020)

Duration of Perioperative Chemotherapy in Locally Advanced Gastric Cancer: A “Less Is More” Question When ypN0 Is Achieved
por: Liu, Zining, et al.
Publicado: (2021)

Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
por: Patnaik, Santosh K., et al.
Publicado: (2021)

Analyzing the impact of minimally invasive surgical approaches on post-operative outcomes of pneumonectomy and sleeve lobectomy patients
por: Nitsche, Lindsay J., et al.
Publicado: (2023)

The Benefit of Post-Mastectomy Radiotherapy in ypN0 Patients after Neoadjuvant Chemotherapy According to Molecular Subtypes
por: Cho, Won Kyung, et al.
Publicado: (2019)

Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis
por: Milano, Michael T, et al.
Publicado: (2020)

Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
por: Kim, Hyun-Ah, et al.
Publicado: (2015)

The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis
por: Yan, Han, et al.
Publicado: (2015)

The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients
por: Wang, Yukun, et al.
Publicado: (2023)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?
por: Hou, X., et al.
Publicado: (2022)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
por: Long, Yaping, et al.
Publicado: (2021)

Prognostic Significance of Twist and N-Cadherin Expression in NSCLC
por: Hui, Linping, et al.
Publicado: (2013)

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
por: Remon, Jordi, et al.
Publicado: (2020)

Indication for and Effect of Adjuvant Chemotherapy for Stage IIa (T3N0M0) Colon Cancer
por: Jeon, Chul-Hyo, et al.
Publicado: (2019)

Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)

Synchronizing N Release from Organic Residues: Opportunities for Integrated Management of N
por: Singh, U., et al.
Publicado: (2001)

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)

Quality of Life After Stereotactic Body Radiation Therapy or Surgery for Early-Stage NSCLC: A Systematic Review
por: Iovoli, Austin J., et al.
Publicado: (2022)

Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer—an east and west multicenter study
por: Huang, Ze-Ning, et al.
Publicado: (2019)

Exploration of the optimal number of regional lymph nodes removed for resected N0 NSCLC patients: A population-based study
por: Yao, Anjie, et al.
Publicado: (2022)

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
por: Fu, Wen-Fen, et al.
Publicado: (2020)

Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021)

Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection
por: Li, Xiao-hui, et al.
Publicado: (2022)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
por: Lu, Jun, et al.
Publicado: (2020)

Do patients receive any benefit from the addition of perioperative immunotherapy-chemotherapy for solid tumors?
por: Quan, Rencui, et al.
Publicado: (2023)

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study
por: Shang, Xiaoling, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6r81g2q4ouamv3h0e94bd6ivcl